Matinas BioPharma Holdings Inc (OTCMKTS:MTNB) informed that it will be demonstrating additional data from the MAT9001 comparative PK and PD study compared to Vascepa(R) at the National Lipid Association Scientific Sessions scheduled from June 11 to June 14, 2015, in Chicago.
The expert comments
Kevin C. Maki, Ph.D., a certified Clinical Lipid Specialist, the CSO and founder of the Midwest Center for Metabolic and Cardiovascular Research, Fellow of the National Lipid Association and also a important affiliate of the company’s Scientific Advisory Board, has been assigned the responsibility to demonstrate the additional data highlighting effects of MAT9001 during an NLA poster question and answer session planned for June 13, 2015.
The drug
Matinas BioPharma’s MAT9001 is a lead metabolic and cardiovascular disease drug candidate. It is a omega-3 fatty acid composition that has the potential to transform into a advanced product for the cure of dyslipidemia. The Company earlier released top-line data from first clinical trial of MAT9001 reflecting superiority compared to Vascepa(R) on primary as well as secondary bioavailability, drop in triglyceride and other lipid endpoints in a comparative PK and PD study. The trial also showed that MAT9001 is the only orally-administered dyslipidemia drug reported to considerably minimize PCSK9 in patients.
The highlights
Vascepa is stated for administered with a lipid-lowering diet to lessen extremely high triglycerides in adult patients. It is a brand of Amarin Pharmaceuticals Ireland Ltd. The NLA is a nonprofit, multidisciplinary medical group with an objective of improving the performance of lipid management in clinical medicine. It represents over 3,500 members in the U.S. and offers continued medical education for healthcare professional and physicians to advance professional development. It will enable them to get certification in clinical lipidology. Matinas BioPharma confirmed that it will mark its presence in the scientific sessions.
On Friday’s trading session, the stock price of Matinas BioPharma Holdings Inc (OTCMKTS:MTNB) opened higher with gains of over 1%.
